NASDAQ:SYN - Synthetic Biologics Stock Price, News & Analysis

$0.40
+0.01 (+2.55 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
$0.40
Now: $0.4017
$0.4258
50-Day Range
$0.39
MA: $0.49
$0.59
52-Week Range
$0.38
Now: $0.4017
$8.00
Volume91,847 shs
Average Volume203,442 shs
Market Capitalization$6.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYN
CUSIPN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$6.75 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.


Synthetic Biologics (NASDAQ:SYN) Frequently Asked Questions

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the NASDAQ under the ticker symbol "SYN."

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Synthetic Biologics.

What is the consensus analysts' recommendation for Synthetic Biologics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synthetic Biologics.

Has Synthetic Biologics been receiving favorable news coverage?

News stories about SYN stock have trended positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Synthetic Biologics earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Synthetic Biologics.

Who are some of Synthetic Biologics' key competitors?

What other stocks do shareholders of Synthetic Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synthetic Biologics investors own include Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Adobe (ADBE), BIOLINERX LTD/S (BLRX), ContraFect (CFRX), Cisco Systems (CSCO), Edge Therapeutics (EDGE), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH) and ImmunoGen (IMGN).

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the folowing people:
  • Mr. Steven A. Shallcross, Interim CEO, CFO, Sec., Treasurer & Sec. (Age 57)
  • Dr. Joseph A. Sliman, Chief Medical Officer (Age 45)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Michael Kaleko M.D., Ph.D., Sr. VP of R&D
  • Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.4017.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $6.75 million. View Additional Information About Synthetic Biologics.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is http://www.syntheticbiologics.com/.


MarketBeat Community Rating for Synthetic Biologics (NASDAQ SYN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe SYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel